<DOC>
	<DOC>NCT00589706</DOC>
	<brief_summary>data from the wistar institute indicated that this anti-body labeled with iodine-125 would localized in the tumor cells of high grade gliomas of the brain. the project combines surgery, radiation therapy, chemotherapy with the labeled antibody in a prospective phase II trial in this disease entity.</brief_summary>
	<brief_title>A Phase II Study of Adjuvant Use of Anti-Epidermal Growth Factor Receptor EGFR-425 in High Grade Gliomas</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>all cases above 18 years of age</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>high grade gliomas of the brain</keyword>
	<keyword>anti-body treatment</keyword>
	<keyword>survival</keyword>
</DOC>